NCT02887859View on ClinicalTrials.gov

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2023

Conditions
Peripheral Artery Disease
Interventions
BIOLOGICAL

Human Acellular Vessel (HAV)

Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques

Trial Locations (5)

27708

Duke University, Durham

48507

Michigan Vascular Center, Flint

94143

UCSF, San Francisco

02115

Brigham and Women's Hospital, Boston

07901

Overlook Medical Center, Summit

Sponsors

Lead Sponsor

Humacyte, Inc.

Collaborators (1)

Atlantic Research Group
All Listed Sponsors
collaborator

Atlantic Research Group

OTHER

lead

Humacyte, Inc.

INDUSTRY